The Hepatitis B Virus X Protein Inhibits Thymine DNA Glycosylase Initiated Base Excision Repair

Maarten A. A. van de Klundert1,2, Formijn J. van Hemert3, Hans L. Zaaijer1,4, Neeltje A. Kootstra2,5

1 Department of Blood-borne Infections, Center for Infection and Immunity Amsterdam (CINIMA), Sanquin, Amsterdam, The Netherlands, 2 Department of Experimental Immunology, CINIMA, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 3 Laboratory of Experimental Virology, Department of Medical Microbiology, CINIMA, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 4 Laboratory of Clinical Virology, Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Abstract

The hepatitis B virus (HBV) genome encodes the X protein (HBx), a ubiquitous transactivator that is required for HBV replication. Expression of the HBx protein has been associated with the development of HBV infection-related hepatocellular carcinoma (HCC). Previously, we generated a 3D structure of HBx by combined homology and ab initio silico modelling. This structure showed a striking similarity to the human thymine DNA glycosylase (TDG), a key enzyme in the base excision repair (BER) pathway. To further explore this finding, we investigated whether both proteins interfere with or complement each other’s functions. Here we show that TDG does not affect HBV replication, but that HBx strongly inhibits TDG-initiated base excision repair (BER), a major DNA repair pathway. Inhibition of the BER pathway may contribute substantially to the oncogenic effect of HBV infection.

Introduction

Infection with hepatitis B virus (HBV) is predominantly cleared in adults, but particularly in younger patients it often leads to chronic infection. As a result of the ongoing viral replication and the immunological response to the infection, about 25% of chronically infected patients develop liver cirrhosis, inflammation and, ultimately, hepatocellular carcinoma (HCC). Although an effective vaccine is available, an estimated 350 million people are currently chronically infected with HBV, resulting in an estimated 600,000 deaths per year.

The HBV genome encodes a ubiquitous transactivator termed the HBV X protein (HBx), which is essential for HBV replication in vitro. Various lines of evidence indicate that HBx is at least partially responsible for the oncogenic effects of chronic HBV infection [1,2]. For instance, HBx is often expressed from integrated parts of the HBV genome in HCC tissue [1,3], and mice expressing HBx in their liver either develop HCC spontaneously [4] or display increased susceptibility to hepatocarcinogens [5]. Also, HBx was shown to impede the nucleotide excision repair (NER) pathway [6–8].

Although the exact function of the HBx protein is still unclear, several functions can be distinguished. HBx acts as a transactivator, which increases the transcription of mRNAs from the covalently closed circular DNA (cccDNA) of HBV by altering its epigenetic context [9]. Transactivational effects are guided by associations between HBx and various transcription factors [10–12]. HBx associates with DDB1 [13–15], and although this interaction is dispensable for the transactivation by HBx [16], it is essential for HBV replication in vivo [17] and for establishing HBV infection in animal models [18,19].

Previously we reported a striking similarity between the predicted structure of the HBx protein and the central domain of DNA glycosylases [20]. DNA glycosylases initiate base excision repair (BER) by glycosylation of the bond between a mismatched base and the phosphate backbone of a DNA strand. Among the proteins showing prominent 3D similarity to HBx is the human thymine DNA glycosylase (TDG). Besides its function in BER, TDG is a key regulator of transcription and involved in the epigenetic regulation of DNA in the context of both transcription and DNA repair [21].

In this paper, we establish a functional relation between HBx and TDG, substantiating the structural homology between HBx and the central domain of a member of the DNA glycosylase family. Our results indicate that TDG does not affect HBV replication in vitro, but we found that HBx strongly inhibits TDG-initiated BER.

Materials and Methods

Cell Culture and Transfection

HEK 293 cells were maintained in Dulbecco’s Modified Eagle Medium without HEPES (DMEM/LONZA, Basel, Switzerland) supplemented with 10% heat inactivated fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) (Gibco Pen Strept). HepG2 cells were maintained in William’s Medium E...
were generated by ligation of annealed primer pairs using Taq DNA ligase. The pG/C and pG/T vectors respectively contained one nucleotide difference resulting in a stop codon at amino acid position 13 for pA/T, which served as a negative control in the assay; a tryptophan at amino acid position 13, which served as a positive control in the assay; a G/T substitution at amino acid position 2 for pA/T, which served as a negative control in the assay; a tryptophan at amino acid position 13 for pA/T, which served as a negative control in the assay; a tryptophan at amino acid position 13, which served as a positive control in the assay; a G/T mismatch and a pA/T (negative control) vectors were generated by ligation of annealed primer pairs using 1.5 pmol EcoR1 and Pst1 digested vector, 15.5 pmol annealed primer pair with two cohesive ends containing EcoR1 and Pst1 sites of pGL3. For the BER assay, the pG/C (positive control), pG/T (mismatch) and pA/T (negative control) vectors were used as a standard curve in each run. Quantification of the BER activity was performed using Roche’s LightCycler® relative quantification software (release 1.5.0).

**BER Assay**

The BER assay was adapted from [24]. The pGL3-control vector (Promega, Madison, USA), containing a SV40 promoter driven luciferase reporter, was modified by insertion of an annealed primer pair with two cohesive NcoI ends containing an EcoR1 and Pst1 sites downstream of the luciferase start codon, into the NcoI site of pGL3. For the BER assay, the pG/C (positive control), pG/T (mismatch) and pA/T (negative control) vectors were generated by ligation of annealed primer pairs using 1.5 pmol EcoR1 and Pst1 digested vector, 15.5 pmol annealed primer pair and 400 units T4 DNA ligase (New England Biolabs) in a final volume of 500 µL. The pA/T, pG/C and pG/T vectors respectively contained one nucleotide difference resulting in a stop codon at amino acid position 13 for pA/T, which served as a negative control in the assay; a tryptophan at amino acid position 13, which served as a negative control in the assay; a tryptophan at amino acid position 13, which served as a positive control in the assay; a G/T mismatch in pG/T, which encodes a stop codon or a tryptophan, depending on whether the vector was repaired or not. The ligation product was purified using the GFX PCR DNA and gel band purification kit (GE Healthcare) and further purified using 5% (HEK 293) or 10% (HepG2) CO2. HepG2 cells were seeded in 6 well plates to reach a confluence of 30–40% at the moment of transfection. The HepG2 cells were transfected with 1 µg of the R9 or R9AX construct per well using calcium phosphate transfection as described above. Increasing concentrations of pHSV-HBX and pMyc-TDG were cotransfected as indicated. After over night incubation, the medium was replaced and cells were maintained in a humidiﬁed incubator at 37°C supplemented with 10% CO2 for 7 days. HepG2 cells were washed with PBS and harvested by trypsin digestion at 37°C for 7 minutes. Trypsin (LONZA, Basel, Switzerland) was inactivated by addition of fresh culture medium and cells were washed with PBS (LONZA, Basel, Switzerland). Cell pellets were lysed in 1 ml isotonic lysis buffer (140 mM NaCl, 1.5 mM MgCl2, 50 mM/L Tris-HCl [pH 8.0]), containing 0.5% Nonidet P-40 for 30 minutes on ice. To quantify capsid-associated HBV DNA, cell nuclei were pelletted at 400 g. Supernatants were harvested and remaining cell debris was removed by 10 minute centrifugation at 21,000 g. Remaining non-encapsidated viral DNA was removed from 200 µl cleared lysate by 1 × nuclease treatment for 45 minutes (Nuclease Mix, GE Healthcare Biosciences). Subsequently encapsidated viral DNA was puriﬁed using the Nucleospin Blood Kit (BIOKE) according to the manufacturer’s instructions. HBV DNA copy number was quantiﬁed by qPCR detecting a part of the core gene using forward primer 5′-GACGAGTTCCATGGAGCATC-3′ and reverse primer 5′-CTGGATCCCTAAGGTCGGTTC-3′ using the LightCycler® 480 system (Roche). The following program was used for qPCR: 10 min 95°C, followed by 50 cycles of 10 sec 95°C, 20 sec 59°C, 30 sec 72°C with a single acquisition during the 72°C step. For quantification of the HBV DNA copy number, the HBV core PCR fragment was cloned in the pGEM®-T Easy vector (Promega) and serial dilutions of this vector were used as a standard curve in each run. Quantification was performed using Roche’s LightCycler® relative quantitation software (release 1.5.0).
purification kit (GE Healthcare) and used for transfection. Transfection of HEK 293 cells was performed in a 96 well plate using 50 ng pG/T, pA/T or pG/C combined with the indicated amounts of pHSV-HBx or pMyc-TDG in 4-fold.

Twenty-four hours after transfection cells were lysed by addition of 25 ul luciferase substrate in concentrated lysis buffer containing 0.83 mM ATP, 0.83 mM luciferine-D, 18.7 mM MgCl₂, 0.78 μM Na₂H₂P₂O₇, 39.9 mM Tris pH 7.8, 0.39% glycerol, 0.03% triton X-100 and 2.6 mM dithiothreitol. Luciferase activity was assessed using a luminometer (Berthold, Bad Wildbad, Germany). The average and standard deviation of the HBV DNA copy number of seven independent experiments is given. *p<0.05, **p<0.01. Significance was determined with a two-sided student’s T test.

doi:10.1371/journal.pone.0048940.g001

Western Blotting

HEK 293T cells were cultured in 6 well plates and transfected with 1 ug of pMyc-TDG or pHSV-HBx per well. After trypsin digestion, the cells were washed with PBS and centrifuged at 400 g for 10 minutes. The cell pellet was lysed in 1 ml of RIPA lysis buffer (150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0) supplemented with Complete® EDTA free protease inhibitor (Roche). The lysate was denatured at 70°C for 10 minutes in 1× NuPAGE LDS sample buffer (Invitrogen) and 0.1 M DTT. Proteins were separated by electrophoresis on a 10% Bis-Tris gel (NuPAGE 10% Bis–Tris precast gel) together with the Odyssey Protein Weight Marker (LI-COR, Lincoln, NE, USA) using MES SDS running buffer (Invitrogen). Subsequently, proteins were transferred to a nitrocellulose membrane (Protran, Schleicher & Schuell, Dassel, Germany; 2 hours 150V) using NuPAGE transfer buffer. Blots were stained over night at 4°C in PBS (Gibco) supplemented with 0.01% Tween 20 (Merck) and 1% Proteín (Nutricia, Schiphol, The Netherlands) with a monoclonal mouse anti-c-Myc antibody (1:5,000; Calbiochem, San Diego, CA, USA) or mouse anti-HSV antibody (1:1,000; Novagen). IRDye 800CW conjugated goat anti-mouse IgG (1:15,000; 926-32210, LI-COR, Tyson, USA).
Western blotting. *pMyc-TDG and HSV-HBx expression in HEK 293T cells was confirmed by concentrations are expressed as ng/ml. EV: empty control vector. (B) Each bar depicts the mean and SEM of four measurements. DNA a reduction of BER activity, regardless of cotransfection of pMyc-TDG. of the pG/T mismatch vector. Co-transfection of pHSV-HBx resulted in positive control, while co-transfection of pMyc-TDG restored the activity activity of the pG/T vector was significantly less than the activity of the mismatch vector and confirming the rate-limiting role of TDG in BER between the two proteins (data not shown). Using western blotting HBx and TDG on BER activity is given as the ratio between the luciferase activity was assessed 24 hours after transfection. The pA/T vector showed only low level of luciferase activity as HBx interferes with TDG initiated BER. Inhibition of BER by the HBV Protein X

First we established whether we could measure an effect of HBx on HBV replication in HepG2 cells. The R9 construct harbouring a 1.2× overlength HBV genome and a mutant R9 construct (R9Δx) not expressing the HBx protein, were transfected in HepG2 cells. In line with other research [25], HBV not expressing HBx was hindered in its replication in HepG2 cells and produced 41% less HBV DNA (Fig. 1A). To ensure that the DNase treatment of the samples efficiently removed plasmid DNA containing the 1.2× overlength HBV genome, the HBV polymerase inhibitor lamivudine (3TC) was added to parallel cultures as a control. HBV DNA production was inhibited by lamivudine in a dose-dependent manner, indicating selective amplification of progeny DNA (Fig. 1B).

To assess the effect of TDG on HBV replication, the R9 and R9Δx vectors were co-transfected with increasing concentrations of plasmids expressing either HSV-tagged HBx (pHSV-HBx) or Myc-tagged TDG (pMyc-TDG). Indeed, replication of R9Δx could be rescued to wild-type level by co-transfection of pHSV-HBx (Fig. 1C). Co-transfection of pMyc-TDG could not rescue replication of the mutant and did not affect replication of the wild-type virus expressing HBx from its genome (Fig. 1D).

HBx Inhibits (TDG initiated) Base Excision Repair

As HBx is a key enzyme in the Base Excision Repair (BER) pathway, we investigated whether HBx could influence TDG initiated repair of a G/T mismatch. We used the glycosylase assay established by Li et al. [24] with some minor adjustments (see materials and methods).

The pG/C (positive control), pG/T (mismatch) and pA/T (negative control) vectors were transfected into HEK 293 cells and luciferase activity was assessed 24 hours after transfection. The pA/T vector showed only low level of luciferase activity as compared to the positive control pG/C vector. We observed an increased luciferase activity of the mismatched pG/T vector as compared to the negative control, indicating that the G/T mismatch is repaired in HEK293 cells to some extent. To analyse the effect of HBx on TDG initiated repair of a G/T mismatch, pHSV-HBx or pMyc-TDG were co-transfected with the pG/C, pA/T and pG/T vectors in HEK293 cells and luciferase activity was analysed 24 hours after transfection. In figure 2A the effect of HBx and TDG on BER activity is given as the ratio between the luciferase activity of pG/T and pG/C vectors corrected for the background luciferase activity of pA/T under the same condition.

Activity of the mismatched vector could be restored to the same level as the positive control by co-transfection of pMyc-TDG (Fig. 2A), proving BER is essential for the activity of the pG/T vector and confirming the rate-limiting role of TDG in BER [26,27]. When pHSV-HBx was co-transfected with the mismatched vector, the luciferase activity was inhibited (Fig. 2; p = 0.036) indicating that HBx inhibits BER of the mismatched pG/T vector in HEK 293 cells. When both pHSV-HBx and pMyc-TDG were cotransfected with the mismatched vector luciferase activity was also inhibited (Fig. 2A), indicating that HBx interferes with TDG initiated BER.

Discussion

Previously we generated a model of the tertiary structure of the HBV X protein by in silico modelling using I-Tasser [20]. The model was validated by successful in silico docking to known HBx binding partners, but no crystal structure of HBx is available to confirm our model. Querying the PDB database for proteins with similar structure, we found that our model of HBx showed striking similarity with the central domain of various members of the MUG family of DNA glycosylases, which are the key enzymes of
the base excision repair pathway. Scoring high among the different glycosylases was the human thymine DNA glycosylase (TDG).

In this study we investigated a functional relation between HBx and TDG. Our results confirm the replication-enhancing role of HBx, in vitro when replication in HepG2 cells was initiated by transfection of a 1.2-kilobase HBV DNA clone that was either capable of or deficient in HBx production. In the same model, we show that HBx, but not TDG could rescue replication of the virus deficient in HBx expression. TDG did not affect the replication of wildtype HBV either, indicating that TDG does not play a direct role in HBV replication. We observed that HBx strongly inhibits the TDG initiated base excision repair of a G/T mismatch in a manner not involving direct interaction between HBx and TDG. Inhibition of BER by HBx could be beneficial to HBV resulting in mutations in the cccDNA pool to allow selection of escape mutants, for instance when infected hepatocytes are subjected to adaptive immune responses. Indeed, an increase in the HBV mutation rate is seen when HBV viremia is suppressed in the course of chronic infection [30,31].

Inhibition of BER may contribute to the chemotherapy resistant phenotype of HBx positive HCC [32], considering that the cytotoxicity of 5-fluorouracil (5-FU) is mediated by TDG-initiated cytotoxicity of 5-FU. Hence, it should be considered that treatment of HBx positive HCC with a DNA damaging chemotherapeutic may be more effective when the agent induces damage that is cytotoxic in the absence of BER.

Because there is no direct interaction between HBx and TDG, it seems likely that HBx interferes with BER by either degrading or interacting in a dominant negative fashion with one of the proteins further downstream the BER pathway. Deregression of DNA repair may benefit the viral replication. Indeed, the use of DNA-damaging agents which disrupt/activate DNA-repair pathways, is strongly associated with reactivation of HBV infections. Although such reactivations are also observed when the immune system is suppressed [37], they are more common [30] and occur earlier [39] when therapy also induces DNA damage. Moreover, the DNA damaging agent doxorubicin strongly induces HBV replication in vitro in the absence of an immune response [39].

In conclusion, our finding that the HBx protein inhibits BER substantiates our hypothesis that there is a structural homology between HBx and the central domain of TDG. The inhibition of BER by HBx might contribute to the oncogenic effect of chronic HBV infection.

**Author Contributions**

Conceived and designed the experiments: MAAvdK NAK HLZ. Performed the experiments: MAAvdK. Analyzed the data: MAAvdK NAK HLZ. Wrote the paper: MAAvdK FjH NAK HLZ.

**References**

1. Kew MC (2011) Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol 26 Suppl 1: 144–152.
2. Neuvet C, Wei Y, Burendia MA (2010) Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 52: 594–604.
3. Liu XH, Liu J, Zhang SH, Zhang SM, Feitelson MA, et al. (2008) COOH-terminal deletion of HBx protein is a frequent event in HBV-associated hepatocellular carcinoma. World J Gastroenterol 14: 1346–1352.
4. Kim CM, Koike K, Saito I, Miyamura T, Jay G (1991) HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351: 317–320.
5. Zhu H, Wang Y, Chen J, Cheng G, Xue J (2004) Transgenic mice expressing hepatitis B virus X protein are more susceptible to carcinogen induced hepatocarcinogenesis. J Hepatol 51: 581–592.
6. Jia L, Wang XW, Harris CC (1999) Hepatitis B virus X protein inhibits nucleotide excision repair. Int J Cancer 80: 875–879.
7. Qadri I, Fatima K, AbdeL-Hafiz H (2011) Hepatitis B virus X protein impedes the DNA repair via its association with transcription factor, TFIIH. BMC Microbiol 11: 48.
8. Mathonet G, Lachance S, Alasou-Jamali M, Drobetzky EA (2004) Expression of hepatitis B virus X oncoprotein inhibits transcription-coupled nucleotide excision repair in human cells. Mutat Res 554: 305–318.
9. Levrero M, Pellecchio T, Petersen J, Belloni L, Raimondo G, et al. (2009) Control of cccDNA function in hepatitis B virus infection. J Hepatol 51: 581–592.
10. Kong HJ, Hong SH, Lee MY, Kim HD, Lee JW, et al. (2000) Direct binding of HBx protein to UVDDB-p127 cellular protein is critical for hepatitis B virus replication. J Virol 74: 75–82.
11. Sitterlin D, Bergametti F, Tiollais P, Tennant BC, Transy C (2000) Correct binding of viral X protein to UVVDD-p127 cellular protein is critical for efficient infection by hepatitis B viruses. Oncogene 19: 4427–4431.
12. van Hemert FJ, van de Klandt MA, Lukashov VV, Kootstra NA, Berkhourt B, et al. (2011) Protein X of hepatitis B virus: origin and structure similarity with the central domain of DNA glycosylase. PLoS One 6: e23392.
13. Cortezza D, Kunz C, Saito Y, Steinacher R, Schar P (2007) The enigmatic thymine DNA glycosylase. DNA Repair (Amst) 6: 489–504.
14. Baumann TF, Rogers SA, Hasegawa K, Liang TJ (1996) Two core promoter mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 98: 2268–2276.
15. Baumann TF, Marrone A, Vergala J, Liang TJ (1998) Naturally occurring mutations define a novel functional form of the hepatitis B virus core promoter in core protein expression. J Virol 72: 6758–6765.
16. Li S, Huang Q, Wang L, Lan Y, Zhang X, et al. (2010) A convenient spectrometric assay system for intracellular quantitative measurement of DNA glycosylase activity. Acta Biochim Biophys Sin (Shanghai) 42: 381–387.
17. Kew MC (2011) Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol 26 Suppl 1: 144–152.
18. Hodgson AJ, Hyser JM, Keady VV, Cang Y, Slagle BL (2012) Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication. Virology 426: 75–82.
19. Sitterlin D, Bergametti F, Tiollais P, Tennant BC, Transy C (2000) Correct binding of viral X protein to UVVDD-p127 cellular protein is critical for efficient infection by hepatitis B viruses. Oncogene 19: 4427–4431.
20. van Hemert FJ, van de Klandt MA, Lukashov VV, Kootstra NA, Berkhourt B, et al. (2011) Protein X of hepatitis B virus: origin and structure similarity with the central domain of DNA glycosylase. PLoS One 6: e23392.
21. Cortezza D, Kunz C, Saito Y, Steinacher R, Schar P (2007) The enigmatic thymine DNA glycosylase. DNA Repair (Amst) 6: 489–504.
22. Baumann TF, Rogers SA, Hasegawa K, Liang TJ (1996) Two core promoter mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 98: 2268–2276.
23. Baumann TF, Marrone A, Vergala J, Liang TJ (1998) Naturally occurring mutations define a novel functional form of the hepatitis B virus core promoter in core protein expression. J Virol 72: 6758–6765.
24. Li S, Huang Q, Wang L, Lan Y, Zhang X, et al. (2010) A convenient spectrometric assay system for intracellular quantitative measurement of DNA glycosylase activity. Acta Biochim Biophys Sin (Shanghai) 42: 381–387.
25. Keady VV, Hodgson AJ, Madden CR, Slagle BL (2007) Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo. J Virol 81: 2656–2662.
26. Visnes T, Akhari M, Hagen L, Slupphaug G, Krokan HE (2008) The rate of base excision repair of uracil is controlled by the initiating glycosylase. DNA Repair (Amst) 7: 1869–1881.
27. Fitzgerald ME, Drohat AC (2008) Coordinating the initial steps of base excision repair. Apurimic/aplysia endonucleosome 1 actively stimulates thymine DNA glycosylase by disrupting the product complex. J Biol Chem 283: 32680–32690.
28. Murakami S, Cheong JH, Kaneko S (1994) Human hepatitis virus X gene encodes a regulatory domain that represses transactivation of X protein. J Biol Chem 269: 1107–1114.
29. Maiti A, Morgan MT, Pozharski E, Drohat AC (2008) Crystal structure of hepatitis B virus X protein. J Biol Chem 283: 32680–32690.
30. van de Klandt MA, Cremer J, Kootstra NA, Boot HJ, Zaaijer HL (2012) Comparison of the hepatitis B virus core, surface and polymerase gene subinfections in chronically infected patients. J Viral Hepat 19: e34–e40.
31. Zaaijer HL, Bouter S, Boot HJ (2006) Substitution rate of the hepatitis B virus surface gene. J Viral Hepat 13: 239–245.
32. Hsu C, Cheng JC, Cheng AL (2006) Recent advances in non-surgical treatment for advanced hepatocellular carcinoma. J Formos Med Assoc 105: 483–493.
33. Kunz C, Focke F, Saito Y, Schuermann D, Lettieri T, et al. (2009) Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biol 7: e91.

34. Chung C, Park SG, Park YM, Jo H, Jung G (2007) Interferon-gamma sensitizes hepatitis B virus-expressing hepatocarcinoma cells to 5-fluorouracil through inhibition of hepatitis B virus-mediated nuclear factor-kappaB activation. Cancer Sci 98: 1758–1766.

35. He Y, Sun HQ, He XE, Wang WL, Lei JH (2010) Knockdown of HBx by RNAi inhibits proliferation and enhances chemotherapy-induced apoptosis in hepatocellular carcinoma cells. Med Oncol 27: 1227–1233.

36. Liu Y, Lou G, Wu W, Zheng M, Shi Y, et al. (2011) Involvement of the NF-kappaB pathway in multidrug resistance induced by HBx in a hepatoma cell line. J Viral Hepat 18: e439–e446.

37. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, et al. (2011) Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 22: 1170–1180.

38. Manzano-Alonso ML, Castellano-Tortajada G (2011) Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 17: 1531–1537.

39. Hsu CH, Hsu HC, Chen HL, Gao M, Yeh PY, et al. (2004) Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res 24: 3035–3040.